Traditional precision oncology approaches, which focus on targeting specific mutations in tumors, often fail to provide lasting benefits for patients with relapsed and refractory solid tumors due to the complex and dynamic nature of the tumor microenvironment. Tumors are not simply collections of cancer cells but intricate ecosystems of interacting cell types that compete for resources and co-evolve, leading to drug resistance.

Alixia is developing tumor ecosystem disruptors that address the limitations of traditional precision oncology by targeting the metabolic and inflammatory interactions within the cancer microenvironment. Their approach aims to collapse tumor ecosystems by impacting multiple cell types, including cancer cells, immune cells, and stromal cells. By studying the interactions between these players, Alixia identifies molecules that can disrupt the triggers that promote oncogenic evolution, suppress immune activation, and drive drug resistance. This strategy enables effective and durable cancer treatment for complex, chronic diseases.

Compounds designed to disrupt metabolic and inflammatory triggers in both cancer and quasi-cancerous cells within the tumor microenvironment.

Research platform integrating biology, biophysics, computational chemistry, and clinical input to drive therapeutic innovation.

Focus on identifying molecules that impact a broad range of cells within the tumor ecosystem.

Therapeutic portfolio consisting of programs at various stages of preclinical development addressing multiple age-related diseases, including solid tumors, neurodegeneration, and immune dysregulation.

The primary target audience includes patients with relapsed and refractory solid tumors who have not responded to traditional therapies, as well as clinicians and researchers seeking new approaches to overcome drug resistance and improve treatment outcomes.